These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30511584)

  • 1. Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
    Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S
    J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective.
    Murray B; Miles-Thomas J; Park AJ; Nguyen VB; Tung A; Gillard P; Lalla A; Nitti VW; Chermansky CJ
    J Comp Eff Res; 2023 Feb; 12(2):e220089. PubMed ID: 36655745
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
    Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
    Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.
    Shepherd JP; Carter-Brooks CM; Chermanksy C
    Int Urogynecol J; 2018 Aug; 29(8):1213-1219. PubMed ID: 29671033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder.
    Tay LJ; Harry D; Malde S; Sahai A
    Urology; 2021 Mar; 149():1-10. PubMed ID: 33227305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service.
    Nazir J; Posnett J; Walker A; Odeyemi IA; Hakimi Z; Garnham A
    J Med Econ; 2015 May; 18(5):390-7. PubMed ID: 25488631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK.
    Autiero SW; Hallas N; Betts CD; Ockrim JL
    BJU Int; 2015 Dec; 116(6):945-54. PubMed ID: 25407358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.